Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.-31. (Canceled)

32. (Previously Presented) A composition comprising:

an effective amount of a biologically active agent;

a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and

a pharmaceutically acceptable carrier;

wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex.

33. (Original) The composition of claim **32**, wherein the biologically active agent is selected from the group consisting of antiviral agents, antibacterial agents, antifungal agents, antiproliferative agents, immunosuppressive agents, vitamins, analgesic agents and hormones.

34. (Original) The composition of claim **33**, wherein the biologically active agent is an antiviral agent selected from the group consisting of acyclovir, famciclovir, ganciclovir, foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine, stavudine, zalcitabine, zidovudine, ribavirin and rimantatine.

35. (Original) The composition of claim **32**, wherein the biologically active agent is an antibacterial agent selected from the group consisting of nafcillin, oxacillin, penicillin, amoxacillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin, norfloxacin, erythromycin and vancomycin.

36. (Original) The composition of claim **32**, wherein the biologically active agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole, ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine, terbinafine and griseofulvin.

37. (Original) The composition of claim **32**, wherein the biologically active agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine, mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.

38. (Previously presented) The composition of claim **32**, wherein the biologically active agent is an immunosuppressive agent selected from the group consisting of methotrexate, azathioprine, fluorouracil, hydroxyurea, 6-thioguanine, chclophosphamide, mechloroethamine hydrochloride, carmustine, cyclosporine, taxol or a phosphate-cleavable taxol conjugate, tacrolimus, vinblastine, dapsone and sulfasalazine.

39. (Original) The composition of claim **32**, wherein the biologically active agent is an analgesic agent selected from the group consisting of lidocaine, bupivacaine, novocaine, procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine ropivacaine and prilocaine.

40. (Previously presented) The composition of claim **32**, wherein the delivery enhancing transporter is a peptide having from about 6 to about 15 amino acids residues wherein from 6 to about 12 residues are selected from the group consisting of L-arginine, D-arginine, L-homoarginine and D-homoarginine.